In the last 10 years, mGluR2 agonists have gained increasing attention for their applications in neurological and psychiatric disorders (Engel et al., 2016; Imre et al., 2006; M. L. Li, Hu, et al., 2015), especially for the treatment of SCZ (Conn et al., 2009; Fell et al., 2012; Patil et al., 2007; Xing et al., 2018). Here, GRM2 is linked to psychiatric disorder.